Novartis Ag (NVS) Net Income (2009 - 2026)
Novartis Ag (NVS) posted Net Income of $3.3 billion for Q2 2026, down 19.06% sequentially from $4.0 billion in Q2 2025, and down 19.06% YoY from $4.0 billion in Q2 2025.
Novartis Ag (NVS) Net Income (2009 - 2026) Analysis & Trends
Novartis Ag has reported Net Income for 18 years, with the latest figure at $3.3 billion in Q2 2026.
- Quarterly Net Income fell 19.06% year-over-year to $3.3 billion in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $3.3 billion (down 72.93% YoY) and the FY2025 annual result came in at $14.0 billion, up 16.99% from the prior year.
- Net Income declined to $3.3 billion in Q2 2026 per NVS's latest filing, from $4.0 billion in the prior quarter.
- Over five years, Net Income peaked at $34001.4 billion in Q1 2022 and troughed at $144.0 million in Q1 2023.
- A 5-year average of $2835.5 billion and a median of $2.0 billion in 2022 frame the typical range for Net Income.
- The sharpest annual moves came in 2023 and 2024: Net Income plunged 100.0% in 2023, then surged 1719.55% in 2024.
- Over 5 years, Net Income stood at $755.0 million in 2022, then plunged by 41.72% to $440.0 million in 2023, then soared by 1719.55% to $8.0 billion in 2024, then plunged by 49.74% to $4.0 billion in 2025, then slipped by 19.06% to $3.3 billion in 2026.
- According to Business Quant data, Net Income over the past three periods registered $3.3 billion, $4.0 billion, and $8.0 billion for Q2 2026, Q2 2025, and Q4 2024 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 645.88 Bn | 625.12 Bn | 17.26 Bn | 5.53 Bn |
| 2 | AbbVie | 463.46 Bn | 456.89 Bn | 12.70 Bn | 3.62 Bn |
| 3 | Merck | 367.92 Bn | 360.78 Bn | 12.21 Bn | -1.34 Bn |
| 4 | Novartis Ag | 297.71 Bn | 290.02 Bn | 11.24 Bn | 3.26 Bn |
| 5 | Astrazeneca | 255.55 Bn | 250.65 Bn | 12.86 Bn | 2.51 Bn |
| 6 | Amgen | 234.52 Bn | 220.53 Bn | 7.24 Bn | 2.38 Bn |
| 7 | Gilead Sciences | 178.22 Bn | 175.04 Bn | 6.22 Bn | -10.50 Bn |
| 8 | Pfizer | 158.57 Bn | 146.88 Bn | 10.94 Bn | -238.00 Mn |
| 9 | Gsk | 105.32 Bn | 101.15 Bn | 8.24 Bn | 207.96 Mn |
| 10 | Sanofi | 54.20 Bn | 46.82 Bn | 10.79 Bn | 17.71 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 3.26 Bn |
| Jun 30, 2025 | 4.02 Bn |
| Dec 31, 2024 | 8.01 Bn |
| Jun 30, 2024 | 3.25 Bn |
| Dec 31, 2023 | 440.00 Mn |
| Sep 30, 2023 | 250.00 Mn |
| Jun 30, 2023 | 2.32 Bn |
| Mar 31, 2023 | 144.00 Mn |
| Dec 31, 2022 | 755.00 Mn |
| Sep 30, 2022 | 245.00 Mn |
| Jun 30, 2022 | 1.70 Bn |
| Mar 31, 2022 | 34,001.37 Bn |
| Dec 31, 2021 | 6.96 Bn |
| Sep 30, 2021 | 1.40 Bn |
| Jun 30, 2021 | 2.90 Bn |
| Mar 31, 2021 | 14,001.31 Bn |
| Dec 31, 2020 | 5.37 Bn |
| Sep 30, 2020 | 18,001.39 Bn |
| Jun 30, 2020 | 1.87 Bn |
| Mar 31, 2020 | 194.00 Mn |